This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowReprints and Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rodgers, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Rodgers, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Technorati  
What's this?
The Journal of Bone and Joint Surgery 82:1807 (2000)
© 2000 The Journal of Bone and Joint Surgery, Inc.

Evidence-Based Orthopaedics

Low-dose aspirin prevented deep venous thrombosis and pulmonary embolism after surgery for hip fracture

A. Rodgers

Sources of funding: Health Research Council, National Heart Foundation, Wishbone Trust, Auckland Orthopaedic Society (New Zealand); National Health and Medical Research Council of Australia; British Heart Foundation; Bayer AG; Sterling Winthrop; Aspirin Foundation; Reckitt and Coleman; SmithKline Beecham.
For correspondence: Dr. A. Rodgers, Clinical Trials Research Unit, Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand.

Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) Trial. Lancet. 2000 Apr 15; 355:1295-302.

Question: In patients having surgery for hip fracture or those having elective arthroplasty, is low-dose aspirin effective in preventing deep venous thrombosis (DVT) and pulmonary embolism (PE)?

Design: Randomized (allocation concealed), blinded (patients, clinicians, and outcome assessors), placebo-controlled trial with 35-day follow-up.

Setting: 148 hospitals in Australia, New Zealand, South Africa, Sweden, and the United Kingdom.

Patients: 13,356 patients (mean age, 79 years; . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Technorati Technorati    What's this?